| Literature DB >> 29912184 |
Nadine Santana-Magal1, Diana Rasoulouniriana1, Corey Saperia1, Amit Gutwillig1, Peleg Rider1, Edgar G Engleman2, Yaron Carmi3.
Abstract
Dendritic cells (DC) are heterogeneous cell populations that differ in their cell membrane markers, migration patterns and distribution, and in their antigen presentation and T cell activation capacities. Since most vaccinations of experimental tumor models require millions of DC, they are widely isolated from the bone marrow or spleen. However, these DC significantly differ from blood and tumor DC in their responses to immune complexes (IC), and presumably to other Syk-coupled lectin receptors. Importantly, given the sensitivity of DC to danger-associated molecules, the presence of endotoxins or antibodies that crosslink activation receptors in one of the isolating steps could result in the priming of DC and thus affect the parameters, or at least the dosage, required to activate them. Therefore, here we describe a detailed protocol for isolating MoDC from blood and tumors while avoiding their premature activation. In addition, a protocol is provided for MoDC activation with tumor IC, and their subsequent analyses.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29912184 PMCID: PMC6101436 DOI: 10.3791/57188
Source DB: PubMed Journal: J Vis Exp ISSN: 1940-087X Impact factor: 1.355